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BACKGROUND: There are anecdotal data that lower levels of vitamin D may be associated with increased levels of toxicity in individuals
receiving chemotherapy; we therefore wished to investigate this further.
METHODS: From a cohort of over 11 000 individuals, we included those who had vitamin D levels (serum 1,25(OH)2D3) measured
before and during chemotherapy. They were analysed for side effects correlating Chemotherapy Toxicity Criteria with vitamin D
levels, normalising data for general markers of patient health including C-reactive protein and albumin.
RESULTS: A total of 241 (2% of the total cohort) individuals entered the toxicity analysis. We found no overall difference in toxicity
effects experienced by patients depending on whether they were vitamin D depleted or had sufficient levels (P¼ 0.78).
CONCLUSION: This pilot study suggests routine vitamin D measurement during treatment does not appear to be necessary
in the management of chemotherapy-induced toxicity.
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Vitamin D deficiency and its relation to chronic illness including
cancer has been the subject of much debate. Some argue that
vitamin D deficiency is central to the causation of cancer and
influential in the pathophysiology at a molecular level (Liu et al,
2003; Schwartz et al, 2005; Ingraham et al, 2008; Manson et al,
2011). However, many suggest that the evidence is, at best,
inadequate to recommend universal measurement and replace-
ment. Although there has been limited data suggesting that
vitamin D deficiency may be a co-factor in chemotherapy-induced
mucocutaneous toxicity (Fink, 2011), to the best of our knowledge
no studies have been conducted to test the association between
vitamin D depletion and chemotherapy toxicity. We therefore
conducted a pilot study to examine this association and asked the
question ‘Does chemotherapy cause more toxicity amongst
patients with vitamin D depletion?’
METHODOLOGY
The oncology cohort at the Leaders in Oncology Care clinic in
London has over 11 000 patients with data prospectively recorded
for the period between May 2005 and September 2011. When
patients attend the clinic for treatment their toxicities are recorded
electronically on the MOSAIQ electronic medical records package
(Elekta, Stockholm, Sweden) using the Chemotherapy Toxicity
Criteria (CTCAE3.0) scale (Trotti et al, 2003). Of the cohort,
455 (4%) patients had their vitamin D levels analysed using
Diasorin Liaison machines (Saluggia, Italy) for serum 1,25(OH)2D3.
The reference range of normal values was 475 nmol l 1. Values
between 25 and 75 nmol l 1 were considered insufficient and those
o25 nmol l 1 considered deficient. The insufficient and deficient
groups were combined to form an ‘abnormal’ group.
A total of 241(2%) patients had vitamin D levels measured
within 6 months of receiving chemotherapy, excluding biological
and hormonal therapies. We studied all Xgrade 2 chemotherapy-
related toxicities among these patients using the CTCAE3.0 scale as
our reference. We recorded the most common toxicities seen and
those that had the most significant impact on the quality of life. We
documented them among various cancer types including palliative,
neo-adjuvant and adjuvant chemotherapies.
Statistical analyses to examine differences between the groups
were performed using the statistical analysis package SPSS,
version 18 (IBM, Armonk, NY, USA). Using Pearson’s w2 analysis,
P-values of p0.05 were interpreted as significant.
To avoid bias because of pro-inflammatory state and general
poor health, we also recorded the C-reactive protein (CRP) and
albumin of these patients and assessed their medians to see if the
groups were comparable. These data were also analysed for various
cancer types to look for any unusual trend in specific cancers.
RESULTS
A total of 165 (68%) patients of the overall study group were found
to have experienced at least one Xgrade 2 toxicity effect, 29 of 41
(71%) in the normal group and 136 of 200 (68%) in the abnormal
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group. The most common overall toxicity effects observed were
pain, fatigue and dry skin. Fatigue, hand–foot reactions and dry
skin were the most common toxicity effects in the normal group
whereas pain, fatigue and hearing loss were the three most
frequent toxicities among patients within the abnormal vitamin D
group. Also, at least one toxicity effect (rated Xgrade 2) was
recorded among 71% of patients in the normal group, 62% in the
insufficient group and 74% in the deficient group.
Upon comparison of the normal and abnormal groups, we were
not able to identify any statistically significant difference in the
total incidence of toxicities recorded (P¼ 0.78). This was also
shown on comparison of normal, insufficient and deficient groups
(Supplementary Table S1).
Dry skin (17% vs 10%), hand–foot reactions (14% vs 5%) and
mucositis (10% vs 6%) had higher percentage frequencies in the
normal group compared with the abnormal group. Although
conversely, neuropathy (7% vs 2%), hypertension (6% vs 0%) and
thrombosis (8% vs 2%) were more frequent in the abnormal group;
the majority of these differences failed to show any statistical
significance (Table 1).
Median CRP and albumin measured in the normal and
abnormal groups were both within normal ranges and the
distribution of cancer types was broadly similar (Table 2).
DISCUSSION
We conducted this pilot study to look for a contributory
relationship of vitamin D depletion in relation to chemotherapy
toxicity as anecdotally we and others noted poor tolerability
among patients with vitamin D depletion, especially, in relation to
skin toxicity and mucositis. There is increasing evidence that
vitamin D is involved in a number of activities in the body other
that its more traditional role in bone modelling and calcium
regulation. For example, vitamin D receptor is believed to
contribute to the regulation of insulin signalling, the response of
macrophages to antigens as well as control of cell proliferation
(Dixon et al, 2005; Chen et al, 2007; Sigmundsdottir et al, 2007;
Bikle, 2010).
This study was planned to look at a causal relationship between
vitamin D levels and chemotherapy toxicities. The long-term aim
was to conduct a larger prospective study looking at significance of
the same and addressing the correlation of vitamin D replacement
therapy to improved chemotherapy toxicity. It was, however,
limited by its small sample size, particularly in the normal
vitamin D group and was also subject to a degree of bias as vitamin D
was predominantly only measured in patients whose levels were
expected to be low. Although tumour types were broadly similar
across the two groups, the fact that because of this many of the
individuals will have been on different chemotherapy regimens can
also be viewed as a limiting factor in the interpretation of the data.
This is also the case when considering that disease stage was not
consistent throughout.
The abnormal group had a number of toxicities observed more
often on a numerical basis than the normal group, including
thrombosis, hypertension, sensory neuropathy and motor neuro-
pathy, but they were not of statistical significance. On further
analysis, by comparing normal and deficient groups, no significant
data was found, further reinforcing the view that there is little
association between vitamin D level and toxicity encountered
during chemotherapy.
We were unable to find any difference between patients with
normal and abnormal vitamin D levels. However, interpretation of
the data was limited by small patient numbers, especially in the
normal group. We believe that bias was minimised by blinding the
researchers to patient names and the objective analysis of the
assessments but we were unable to determine the vitamin D
supplementation status for all patients during their chemotherapy
treatment. Despite these limitations the observation that there
were no major differences between the two groups suggests, at
least in this study, that vitamin D measurement in unlikely to
change significantly the management of oncology patients on
chemotherapy.
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Allergic reaction 0 (0) 1 (1) 0.65
Anorexia 2 (5) 13 (7) 0.70
Carpal tunnel syndrome 0 (0) 1 (1) 0.65
Constipation 4 (10) 19 (10) 0.96
Cough 0 (0) 6 (3) 0.23
Desquamation 0 (0) 6 (3) 0.26
Diarrhoea 4 (10) 19 (10) 0.96
Dry skin 7 (17) 19 (10) 0.15
Fatigue 9 (22) 38 (19) 0.67
Fever 0 (0) 1 (1) 0.65
Hand–foot reaction 6 (14) 9 (5) 0.01*
Hearing loss 3 (7) 20 (10) 0.96
Hot flushes 0 (0) 1 (1) 0.65
Hypertension 0 (0) 11 (6) 0.11
Injection site reaction 1 (2) 0 (0) 0.03*
Insomnia 5 (12) 8 (4) 0.03*
Memory loss 0 (0) 1 (1) 0.65
Mood changes 0 (0) 8 (4) 0.19
Motor neuropathy 1 (2) 9 (5) 0.55
Mucositis 4 (10) 11 (6) 0.30
Nail changes 1 (2) 0 (0) 0.03*
Pain 5 (12) 43 (21) 0.18
Painful rash 2 (5) 11 (6) 0.87
Sensory neuropathy 1 (2) 13 (7) 0.31
Taste changes 1 (2) 8 (4) 0.03*
Thrombosis 1 (2) 16 (8) 0.21
Vomiting 0 (0) 12 (6) 0.11
Weight gain 1 (2) 0 (0) 0.03*
*Statistically significant.






Breast 17 (41) 69 (35)
Colorectal 10 (24) 58 (29)
Lunga 5 (12) 19 (10)
Lymphoma/haematological 1 (2) 3 (2)
Head and neckb 0 (0) 3 (2)
Gynaecological 0 (0) 11 (6)
Pancreatic and small intestine 3 (7) 15 (8)
Urologicalc 3 (7) 11 (6)
Cancer of unknown primary 1 (2) 4 (2)
aIncluding mesothelioma. bIncluding pyriform sinus and tonsillar fossa. cIncluding
kidneys, bladder, prostate and testes.
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